1. Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression.
NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. (A) Individual TMEM scores of 20 patients before and after receiving NAC, which included weekly paclitaxel (80 mg/m2 × 12 consecutive weeks) followed sequentially by dose-dense AC chemotherapy [doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) every 2 weeks × four cycles, plus pegfilgrastim (6 mg, subcutaneously) on day 2 of each cycle]. The patients did not receive tamoxifen. Red line: TMEM high-risk cutoff point according to (5). (B) Representative images of TMEM triple-stain IHC in patients #3 and #7 in the pre-NAC core biopsies (upper panels) and post-NAC resected tumors (lower panels). Scale bar, 50 μm. (C) Mean TMEM scores in the 20 human breast cancers shown in (A), before and after receiving NAC, Wilcoxon test. (D) Representative images of MENAINV protein expression, as visualized by MENAINV IF and DAPI in a patient receiving NAC. Scale bar, 100 μm. (E) Quantification of the MENAINV-positive area in pre- and post-NAC patient samples. Assay performed in only seven of the patients shown in (A) because of limited availability of pre-NAC biopsy material for the remaining 13 patients. Mann-Whitney U test. (F) MENAINV gene expression, as assessed by real-time RT-PCR, in FNA biopsies taken from five breast cancer patients before and after 2 weeks of receiving NAC with paclitaxel.
George S. Karagiannis et al., Sci Transl Med 2017;9:eaan0026
Published by AAAS